Published in Dalton Trans on December 17, 2009
Misfolded proteins in Alzheimer's disease and type II diabetes. Chem Soc Rev (2011) 1.45
Design of small molecules that target metal-A{beta} species and regulate metal-induced A{beta} aggregation and neurotoxicity. Proc Natl Acad Sci U S A (2010) 1.37
Hydrogen peroxide activated matrix metalloproteinase inhibitors: a prodrug approach. Angew Chem Int Ed Engl (2010) 1.29
Insights into antiamyloidogenic properties of the green tea extract (-)-epigallocatechin-3-gallate toward metal-associated amyloid-β species. Proc Natl Acad Sci U S A (2013) 1.12
Prochelator BHAPI protects cells against paraquat-induced damage by ROS-triggered iron chelation. Metallomics (2012) 1.04
Bifunctional compounds for controlling metal-mediated aggregation of the aβ42 peptide. J Am Chem Soc (2012) 1.03
8-Hydroxyquinolines: a review of their metal chelating properties and medicinal applications. Drug Des Devel Ther (2013) 0.97
Development of bifunctional stilbene derivatives for targeting and modulating metal-amyloid-β species. Inorg Chem (2011) 0.95
Recent Development of Bifunctional Small Molecules to Study Metal-Amyloid-β Species in Alzheimer's Disease. Int J Alzheimers Dis (2010) 0.95
Alzheimer's disease & metals: therapeutic opportunities. Br J Pharmacol (2011) 0.93
Reactivity of diphenylpropynone derivatives toward metal-associated amyloid-β species. Inorg Chem (2012) 0.90
Chelators for investigating zinc metalloneurochemistry. Curr Opin Chem Biol (2013) 0.90
Activation of sulfonate ester based matrix metalloproteinase proinhibitors by hydrogen peroxide. J Biol Inorg Chem (2010) 0.85
A prochelator activated by beta-secretase inhibits Abeta aggregation and suppresses copper-induced reactive oxygen species formation. J Am Chem Soc (2010) 0.85
Clawing back: broadening the notion of metal chelators in medicine. Curr Opin Chem Biol (2013) 0.83
Tris(2-pyridylmethyl)amine (TPA) as a membrane-permeable chelator for interception of biological mobile zinc. Metallomics (2013) 0.81
Prochelators triggered by hydrogen peroxide provide hexadentate iron coordination to impede oxidative stress. J Inorg Biochem (2011) 0.81
A potent antioxidant small molecule aimed at targeting metal-based oxidative stress in neurodegenerative disorders. Chem Commun (Camb) (2013) 0.80
Exploring the reactivity of flavonoid compounds with metal-associated amyloid-β species. Dalton Trans (2012) 0.78
Neuroprotective Role of a Novel Copper Chelator against Aβ 42 Induced Neurotoxicity. Int J Alzheimers Dis (2013) 0.78
Intracellular reduction/activation of a disulfide switch in thiosemicarbazone iron chelators. Metallomics (2014) 0.78
A boronate prochelator built on a triazole framework for peroxide-triggered tridentate metal binding. Inorganica Chim Acta (2012) 0.78
A multifunctional, light-activated prochelator inhibits UVA-induced oxidative stress. Bioorg Med Chem Lett (2015) 0.77
A Redox-Active, Compact Molecule for Cross-Linking Amyloidogenic Peptides into Nontoxic, Off-Pathway Aggregates: In Vitro and In Vivo Efficacy and Molecular Mechanisms. J Am Chem Soc (2015) 0.77
Overview of Alzheimer's Disease and Some Therapeutic Approaches Targeting Aβ by Using Several Synthetic and Herbal Compounds. Oxid Med Cell Longev (2015) 0.77
Combining conformational sampling and selection to identify the binding mode of zinc-bound amyloid peptides with bifunctional molecules. J Comput Aided Mol Des (2012) 0.76
Bimodal-hybrid heterocyclic amine targeting oxidative pathways and copper mis-regulation in Alzheimer's disease. Metallomics (2014) 0.75
Structure-mechanism-based engineering of chemical regulators targeting distinct pathological factors in Alzheimer's disease. Nat Commun (2016) 0.75
Multi-target-directed phenol-triazole ligands as therapeutic agents for Alzheimer's disease. Chem Sci (2017) 0.75
A rationally designed small molecule for identifying an in vivo link between metal-amyloid-β complexes and the pathogenesis of Alzheimer's disease. Chem Sci (2015) 0.75
Metals, toxicity and oxidative stress. Curr Med Chem (2005) 7.48
Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov (2004) 5.82
Oxidative stress and neurodegeneration: where are we now? J Neurochem (2006) 5.44
Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci (2004) 5.37
Mechanisms for copper acquisition, distribution and regulation. Nat Chem Biol (2008) 4.03
Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol (2003) 3.58
Iron homeostasis. Annu Rev Physiol (2007) 3.22
Mammalian zinc transport, trafficking, and signals. J Biol Chem (2006) 3.05
Amyloid beta-protein assembly and Alzheimer disease. J Biol Chem (2008) 2.90
Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis). Chem Rev (2006) 2.59
The metallobiology of Alzheimer's disease. Trends Neurosci (2003) 2.47
Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics (2009) 2.36
Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron (2008) 2.30
The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev (2005) 2.22
Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic Biol Med (1997) 1.99
Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J Biol Chem (2002) 1.99
Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem (2008) 1.81
Nanoparticles in cellular drug delivery. Bioorg Med Chem (2009) 1.70
Modifications of boronic ester pro-chelators triggered by hydrogen peroxide tune reactivity to inhibit metal-promoted oxidative stress. Dalton Trans (2007) 1.70
A pro-chelator triggered by hydrogen peroxide inhibits iron-promoted hydroxyl radical formation. J Am Chem Soc (2006) 1.64
Copper and iron disorders of the brain. Annu Rev Neurosci (2007) 1.62
Bioinorganic chemistry of copper and zinc ions coordinated to amyloid-beta peptide. Dalton Trans (2008) 1.61
Iron misregulation in the brain: a primary cause of neurodegenerative disorders. Lancet Neurol (2003) 1.57
Integrin alpha v beta 3-targeted imaging of lung cancer. Neoplasia (2005) 1.54
Design, selection, and characterization of thioflavin-based intercalation compounds with metal chelating properties for application in Alzheimer's disease. J Am Chem Soc (2009) 1.32
The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. Br J Pharmacol (2005) 1.32
Iron and activated oxygen species in biology: the basic chemistry. Biometals (1999) 1.31
Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg Med Chem (2005) 1.27
Hydrogen peroxide is generated during the very early stages of aggregation of the amyloid peptides implicated in Alzheimer disease and familial British dementia. J Biol Chem (2005) 1.26
In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in an orthotopic glioblastoma model. Mol Imaging Biol (2006) 1.26
Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer's disease. J Biol Chem (1996) 1.17
Synthesis, characterization, and metal coordinating ability of multifunctional carbohydrate-containing compounds for Alzheimer's therapy. J Am Chem Soc (2007) 1.10
Iron prochelator BSIH protects retinal pigment epithelial cells against cell death induced by hydrogen peroxide. J Inorg Biochem (2008) 1.07
The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects. Curr Med Chem (2004) 1.06
Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases. Eur J Pharm Biopharm (2005) 1.05
Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease. J Med Chem (2007) 1.05
Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neurosci Lett (2006) 1.05
Iron on the brain. Nat Genet (2001) 1.04
Why is the amyloid beta peptide of Alzheimer's disease neurotoxic? Dalton Trans (2008) 1.02
Combating Alzheimer's disease with multifunctional molecules designed for metal passivation. Angew Chem Int Ed Engl (2007) 1.01
Iron chelator research: past, present, and future. Curr Med Chem (2003) 1.01
Novel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions. Ann N Y Acad Sci (2004) 1.01
Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors. J Pharmacol Exp Ther (1995) 1.00
Ultraviolet A radiation induces immediate release of iron in human primary skin fibroblasts: the role of ferritin. Proc Natl Acad Sci U S A (1999) 0.99
Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis. Exp Gerontol (2004) 0.98
Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann N Y Acad Sci (2004) 0.98
Novel near-infrared fluorescent integrin-targeted DFO analogue. Bioconjug Chem (2007) 0.96
Sequestration of copper from beta-amyloid promotes selective lysis by cyclen-hybrid cleavage agents. J Biol Chem (2008) 0.96
Altering pyridinone N-substituents to optimise activity as potential prodrugs for Alzheimer's disease. Dalton Trans (2008) 0.95
Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease. J Neurochem (2006) 0.95
Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases. J Neural Transm (Vienna) (2004) 0.94
Design of targeting ligands in medicinal inorganic chemistry. Chem Soc Rev (2006) 0.94
The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30. Curr Alzheimer Res (2006) 0.93
Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents. Prog Neurobiol (2007) 0.92
Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron- chelating- antioxidants, M-30 and green tea polyphenol, EGCG. Curr Alzheimer Res (2007) 0.91
Inhibition of catechol-O-methyltransferase (COMT) as well as tyrosine and tryptophan hydroxylase by the orally active iron chelator, 1,2-dimethyl-3-hydroxypyridin-4-one (L1, CP20), in rat brain in vivo. Biochem Pharmacol (1993) 0.90
Contribution of redox-active iron and copper to oxidative damage in Alzheimer disease. Ageing Res Rev (2004) 0.89
Metal trafficking: from maintaining the metal homeostasis to future drug design. Metallomics (2009) 0.87
New drug delivery strategies for improved Parkinson's disease therapy. Expert Opin Drug Deliv (2009) 0.87
Metal complexes as artificial proteases: toward catalytic drugs. Curr Opin Chem Biol (2008) 0.86
Cleavage agents for soluble oligomers of amyloid beta peptides. Angew Chem Int Ed Engl (2007) 0.86
Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective-neurorestorative moieties for Alzheimer's therapy. J Med Chem (2009) 0.86
Structure-activity investigation of the inhibition of 3-hydroxypyridin-4-ones on mammalian tyrosine hydroxylase. Biochem Pharmacol (2001) 0.86
Iron overload, oxidative stress, and axonal dystrophy in brain disorders. Pediatr Neurol (2001) 0.86
Design, synthesis, and evaluation of novel 2-substituted 3-hydroxypyridin-4-ones: structure-activity investigation of metalloenzyme inhibition by iron chelators. J Med Chem (2002) 0.86
Nanoparticle-chelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease. Neurosci Lett (2009) 0.85
Synthesis and evaluation of iron chelators with masked hydrophilic moieties. J Am Chem Soc (2002) 0.85
Caged-iron chelators a novel approach towards protecting skin cells against UVA-induced necrotic cell death. J Invest Dermatol (2006) 0.85
Dihydrolipoic acid lowers the redox activity of transition metal ions but does not remove them from the active site of enzymes. Redox Rep (2004) 0.84
Antiparkinson prodrugs. Molecules (2008) 0.84
L-dopa- and dopamine-(R)-alpha-lipoic acid conjugates as multifunctional codrugs with antioxidant properties. J Med Chem (2006) 0.82
A Novel iron-chelating derivative of the neuroprotective peptide NAPVSIPQ shows superior antioxidant and antineurodegenerative capabilities. J Med Chem (2007) 0.82
Glycosylated tetrahydrosalens as multifunctional molecules for Alzheimer's therapy. Dalton Trans (2009) 0.79
Novel potential neuroprotective agents with both iron chelating and amino acid-based derivatives targeting central nervous system neurons. Biochem Pharmacol (2005) 0.79
Novel neuroprotective neurotrophic NAP analogs targeting metal toxicity and oxidative stress: potential candidates for the control of neurodegenerative diseases. J Neural Transm Suppl (2006) 0.79
N,N'-bis-dibenzyl ethylenediaminediacetic acid (DBED): a site-specific hydroxyl radical scavenger acting as an "oxidative stress activatable" iron chelator in vitro. Free Radic Res (1995) 0.78
3,5-Disubstituted-4-hydroxyphenyls linked to 3-hydroxy-2-methyl-4(1H)-pyridinone: potent inhibitors of lipid peroxidation and cell toxicity. J Med Chem (2000) 0.77
EDTA bis-(ethyl phenylalaninate): a novel transition metal-ion chelating hydroxyl radical scavenger with a potential anti-inflammatory role. Bioorg Med Chem Lett (2001) 0.77
Protection against oxidative damage by iron chelators: effect of lipophilic analogues and prodrugs of N,N'-bis(3,4,5-trimethoxybenzyl)ethylenediamine- N,N'-diacetic acid (OR10141). J Med Chem (2000) 0.77
N,N'-bis-(3,4,5-trimethoxybenzyl) ethylenediamine N,N'-diacetic acid as a new iron chelator with potential medicinal applications against oxidative stress. Biochem Pharmacol (1996) 0.76
Prodrug and covalent linker strategies for the solubilization of dual-action antioxidants/iron chelators. Bioorg Med Chem Lett (2002) 0.76
Synthesis and biological evaluation of lipophilic iron chelators as protective agents from oxidative stress. Org Biomol Chem (2005) 0.76
Modifications of boronic ester pro-chelators triggered by hydrogen peroxide tune reactivity to inhibit metal-promoted oxidative stress. Dalton Trans (2007) 1.70
A pro-chelator triggered by hydrogen peroxide inhibits iron-promoted hydroxyl radical formation. J Am Chem Soc (2006) 1.64
Application of metal coordination chemistry to explore and manipulate cell biology. Chem Rev (2009) 1.56
A Mets motif peptide found in copper transport proteins selectively binds Cu(I) with methionine-only coordination. Inorg Chem (2005) 1.25
Protein alignment by a coexpressed lanthanide-binding tag for the measurement of residual dipolar couplings. J Am Chem Soc (2003) 1.25
Coordination chemistry of copper proteins: how nature handles a toxic cargo for essential function. J Inorg Biochem (2011) 1.20
Structural origin of the high affinity of a chemically evolved lanthanide-binding peptide. Angew Chem Int Ed Engl (2004) 1.19
A powerful combinatorial screen to identify high-affinity terbium(III)-binding peptides. Chembiochem (2003) 1.12
A prochelator activated by hydrogen peroxide prevents metal-induced amyloid Beta aggregation. Chembiochem (2010) 1.12
Fe(III)-coordination properties of neuromelanin components: 5,6-dihydroxyindole and 5,6-dihydroxyindole-2-carboxylic acid. Inorg Chem (2006) 1.08
Iron prochelator BSIH protects retinal pigment epithelial cells against cell death induced by hydrogen peroxide. J Inorg Biochem (2008) 1.07
Prochelator BHAPI protects cells against paraquat-induced damage by ROS-triggered iron chelation. Metallomics (2012) 1.04
Coordination of platinum therapeutic agents to met-rich motifs of human copper transport protein1. Metallomics (2009) 1.03
Model peptides provide new insights into the role of histidine residues as potential ligands in human cellular copper acquisition via Ctr1. J Am Chem Soc (2011) 1.01
Methionine motifs of copper transport proteins provide general and flexible thioether-only binding sites for Cu(I) and Ag(I). J Biol Inorg Chem (2010) 0.94
Keys for unlocking photolabile metal-containing cages. Angew Chem Int Ed Engl (2010) 0.93
Phosphorylation-dependent metal binding by alpha-synuclein peptide fragments. J Biol Inorg Chem (2006) 0.92
A comparison of methionine, histidine and cysteine in copper(I)-binding peptides reveals differences relevant to copper uptake by organisms in diverse environments. Metallomics (2010) 0.90
Probing oxidative stress: Small molecule fluorescent sensors of metal ions, reactive oxygen species, and thiols. Coord Chem Rev (2012) 0.90
Phosphorylation of an alpha-synuclein peptide fragment enhances metal binding. J Am Chem Soc (2005) 0.90
A prochelator activated by beta-secretase inhibits Abeta aggregation and suppresses copper-induced reactive oxygen species formation. J Am Chem Soc (2010) 0.85
A photolabile ligand for light-activated release of caged copper. J Am Chem Soc (2008) 0.84
Toward the development of prochelators as fluorescent probes of copper-mediated oxidative stress. Dalton Trans (2009) 0.83
Prochelators triggered by hydrogen peroxide provide hexadentate iron coordination to impede oxidative stress. J Inorg Biochem (2011) 0.81
Counterions influence reactivity of metal ions with cysteinyldopa model compounds. Inorg Chem (2007) 0.80
Pharmacological activity of metal binding agents that alter copper bioavailability. Dalton Trans (2015) 0.79
A prochelator with a modular masking group featuring hydrogen peroxide activation with concurrent fluorescent reporting. Chem Commun (Camb) (2014) 0.79
Characterization of a photoswitching chelator with light-modulated geometric, electronic, and metal-binding properties. Inorg Chem (2014) 0.78
A boronate prochelator built on a triazole framework for peroxide-triggered tridentate metal binding. Inorganica Chim Acta (2012) 0.78
Monitoring β-secretase activity in living cells with a membrane-anchored FRET probe. Angew Chem Int Ed Engl (2012) 0.78
Toward the detection of cellular copper(II) by a light-activated fluorescence increase. Inorg Chem (2010) 0.78
Development of next-generation photolabile copper cages with improved copper binding properties. Dalton Trans (2010) 0.78
Copper shares a piece of the pi. Nat Chem Biol (2008) 0.77
Synthesis and characterization of copper(II) complexes of cysteinyldopa and benzothiazine model ligands related to pheomelanin. Inorg Chem (2006) 0.76
Introduction to "cellular metal homeostasis and trafficking". Chem Rev (2009) 0.76
A Cell-Permeable Fluorescent Prochelator Responds to Hydrogen Peroxide and Metal Ions by Decreasing Fluorescence. Inorganica Chim Acta (2012) 0.76
Light uncages a copper complex to induce nonapoptotic cell death. Chem Commun (Camb) (2013) 0.75
The highways and byways of bioinorganic chemistry. Curr Opin Chem Biol (2010) 0.75
A comparison of methionine, histidine and cysteine in copper(I)-binding peptides reveals differences relevant to copper uptake by organisms in diverse environments. Metallomics (2011) 0.75
Preface. Biometals 2014--Proceedings of the 9th International Symposium Biometals 2014 at Duke University, Durham, NC, USA. Biometals (2015) 0.75
Application of inorganic chemistry for non-cancer therapeutics. Dalton Trans (2012) 0.75